Quick Takeaways
- Jeffrey L. Gendell filed SCHEDULE 13G/A for Avadel Pharmaceuticals plc American Depositary Shares, each representing one Ordinary Share, nominal value $0.01 per share (AVDL).
- Disclosed ownership: 4.9%.
- Date of event: 31 Dec 2025.
Jeffrey L. Gendell - 31 Dec 2025 SCHEDULE 13G/A Report for Avadel Pharmaceuticals plc American Depositary Shares, each representing one Ordinary Share, nominal value $0.01 per share (AVDL)
- Filing Manager
- Jeffrey L. Gendell
- Reporting Manager
- Jeffrey L. Gendell
- Symbol
- AVDL
- Shares outstanding
- 98,762,388 shares
- Disclosed Ownership
- 4,839,357 shares
- Ownership
- 4.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 06 Feb 2026, 17:55:18 UTC
- Date of event
- 31 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Jeffrey L. Gendell disclosed 4.9% ownership in Avadel Pharmaceuticals plc American Depositary Shares, each representing one Ordinary Share, nominal value $0.01 per share (AVDL) on 31 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 06 Feb 2026, 17:55.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Tontine Asset Associates, LLC | 2.9% | 2,859,475 | 0 | 2,859,475 | Jeffrey L. Gendell | Managing Member | |
| Tontine Capital Overseas Master Fund II, L.P. | 2.9% | 2,859,475 | 0 | 2,859,475 | Jeffrey L. Gendell | Managing Member of Tontine Asset Associates, LLC, the general partner of Tontine Capital Overseas Master Fund II, L.P. | |
| Jeffrey L. Gendell | 4.9% | 4,839,357 | 70,000 | 4,769,357 | Jeffrey L. Gendell | Jeffrey L. Gendell |